Sanofi and Regeneron announced that Japan's Ministry of Health approved Dupixent for children aged 6 to 11 with severe asthma. It was previously only authorized for patients 12 and older in the region. The approval is based on Phase 3 trial data showing the drug reduced severe exacerbations by 54% to 65% and improved lung function compared to placebo. Dupixent is now approved in over 50 countries for this specific age group.